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Abstract. Celiac disease (CD) is a multifactorial chronic inflammatory condition 
that results in injury of the mucosal lining of the small intestine upon ingestion of 
wheat gluten and related proteins from barley and rye. Although the exact 
mechanisms leading to CD are not fully understood, the genetic basis of CD has 
been relatively well characterized. In this review we briefly review the history of 
discovery, clinical presentation, pathophysiology, and current understanding of 
the genetics underlying CD risk. Then, we discuss what is known about the 
current distribution and evolutionary history of genes underlying CD risk in light 
	  
of other evolutionary models of disease. Specifically, we conclude that the set of 
loci underlying CD risk did not cohesively evolve as a response to a single past 
selection event such as the development of agriculture. Rather, deterministic and 
stochastic evolutionary processes have both contributed to the present distribution 
of variation in CD risk loci. Selection has shaped some components of this 
network, but this selection appears to have occurred at different points in the past. 
Other parts of the CD risk network have likely arisen due to stochastic processes 
such as genetic drift. 
 
Celiac disease (CD) is a multifactorial chronic inflammatory condition that results 
in injury of the mucosal lining of the small intestine.  The earliest descriptions of 
a condition with symptoms like CD date back to the first and second century 
writings of the Greek physician Arataeus (Simoons 1981; Losowsky 2008). The 
first modern description of CD is attributed to English physician Samuel Jones 
Gee, who was familiar with the writings of Arataeus.  In 1888 (Dowd and 
Walker-Smith 1974; Simoons 1981; Losowsky 2008) Gee described the ‘coeliac 
affection’ as a condition of chronic indigestion associated with diarrhea, wasting, 
and weakness and common in people of all ages.  Gee’s report was the first to 
hypothesize dietary factors as a primary cause of the condition (Dowd and 
Walker-Smith 1974), and during the early twentieth century some workers noted 
the value of a starch free diet for prevention of CD (Haas 1924). Dicke and 
	  
colleagues (1950, 1953) observed the detrimental effect of wheat flour (but not 
wheat starch) on CD patients experimentally confirming a role for diet as a driver 
of CD. Shortly thereafter, Anderson and colleagues (Anderson et al. 1952; Alvey 
et al. 1957) confirmed the effect of wheat on CD and identified wheat gluten as 
the primary culprit. 
 CD appears to be an evolutionary paradox. Only since the 1950s have 
clinicians recognized that a gluten-free diet is an effective treatment (Barker and 
Liu 2008). Before that time, diagnosed and undiagnosed CD reduced the health 
and fitness of sufferers, with juvenile cases leading to malnutrition or death, and 
adult cases causing wasting, lack of adequate nutrition, greater susceptibility to 
infection, and direct reductions in fertility (Corrao et al. 2001; Soni and Badawy 
2010). Despite these apparent costs, CD is common today (>1%) in several 
populations with long histories of wheat agriculture, including Europe, the Near 
East, and North Africa (Catassi et al. 1996; Corrao et al. 1996; Mäki et al. 2003; 
Rubio-Tapia et al. 2012). CD occurs at even higher frequencies in some parts of 
these regions, reaching 5–6% among the Saharawi of northern Africa (Catassi et 
al. 1999, 2001). There is little evidence that the present incidence of CD in these 
populations can be explained by shifts in the environment, such as the “hygiene 
effect” of lower pathogen and parasite loads that has been suggested to explain 
increases in allergies and asthma. Both historical and archaeological evidence 
show that CD was present in these populations before industrialization. Recent 
	  
diet shifts across much of this region have likely decreased the role of dietary 
gluten, due to the adoption of maize, rice and other staple alternatives to wheat, 
and more widespread use of refined flours with low gluten content. 
 The paradox of high CD incidence in these populations despite the evident 
fitness costs seems to require some evolutionary explanation. Similarly, common 
human disorders that have a fitness cost in one or more populations, such as 
variegate porphyria, sickle-cell anemia, and cystic fibrosis, have been explained 
either as a result of selective balances or founder effects. In contrast to such 
examples, in which a single locus is implicated, CD is genetically complex. The 
additive variance underlying CD risk can so far be attributed to more than 40 
genetic loci identified in genome-wide association or case-control studies. The 
strongest of these associations are in the Human Leukocyte Antigen (HLA) region 
of the genome, which much evidence shows to be subject to recent natural 
selection (Albrechtsen et al. 2010). But the larger network of more than 40 other 
risk loci presents a potentially much more complex story than the well-known 
single-gene examples of founder effects and balancing selection. 
 In this review we briefly cover the clinical presentation, pathophysiology, 
and current understanding of the genetics underlying CD risk.  Then, we discuss 
what is known about the current distribution and evolutionary history of genes 
underlying CD risk in light of other evolutionary models of disease. 
 
	  
Presentation, Pathophysiology, and Genetics of CD 
Clinical Presentation and Treatment. The clinical presentation of CD is highly 
variable and depends on age (Fasano 2005; Barker and Liu 2008). Classical 
symptoms include abdominal pain and distension, diarrhea, malnutrition, and 
failure to thrive within the first few years of life (Barker and Liu 2008). CD is 
often recognized based on its characteristic damage to the mucosal lining of the 
small intestine. The scoring system developed by Marsh (1992) ranges from 
normal upper intestinal histology to increasing levels of crypt hyperplasia often 
accompanied by intraepithelial lymphocytes and ending in any degree of villous 
atrophy.  Recent diagnoses have been assessed using the presence of tissue 
transglutaminase (TGase) autoantibodies, such as immunoglobulin A (IgA), and 
then confirmed after intestinal biopsy by response to treatment with a gluten-free 
diet (GFD) (Farrell and Kelly 2002). 
 The complications of CD go far beyond the classical symptoms into other 
aspects of biology and health. CD can cause vitamin (D and K) and micronutrient 
(calcium, iron, folate) deficiencies, with prolonged cases often leading to 
conditions such as rickets, osteoporosis, and anemia (Farrell and Kelly 2002; 
Fasano 2005; Green and Cellier 2007). Linear enamel hypoplasias on the teeth, a 
marker of nutritional stress, have been noted in greater than twenty percent of CD 
cases in children (Bucci et al. 2007; Campisi et al. 2007; Cheng et al. 2010, but 
see Procaccini et al. 2007, for a contrasting result). Neurological abnormalities 
	  
including hypotonia, developmental delay, learning disorders and ADHD, 
headache, and cerebellar ataxia have also been reported to be more common in 
children with CD (Zelnik et al. 2004). Patients with CD have a slightly increased 
risk for developing gastrointestinal malignancies such as adenocarcinoma (Barker 
and Liu 2008).  As noted above, complications from CD may also include 
reduced fertility and increased mortality (Corrao et al. 2001; Soni and Badawy 
2010). 
 Celiac disease is unusually common among certain autoimmune disease 
cohorts. Several researchers have noted a high occurrence of CD in patients 
diagnosed with type 1 diabetes mellitus (T1DM) (Greco et al. 2012; Pham Short 
et al. 2012). Increased prevalence of CD among autoimmune thyroid disease 
sufferers has also been frequently noted (reviewed in Ch'ng et al. 2007).  These 
conditions share with CD an association with risk haplotypes HLA-DQ2 and 
HLA-DQ8 (Ch'ng et al. 2007; Pham Short et al. 2012). In addition to T1DM, 
shared (non-HLA) genetic risk factors with CD have been noted for Crohn’s 
disease (CrD) (Festen et al. 2011) and rheumatoid arthritis (RA) (Zhernakova et 
al. 2011). 
 The wide range of clinical symptoms and complications associated with 
CD, particularly those that are more severe in children, support the interpretation 
of CD as an evolutionary paradox.  Prior to the recent discovery of gluten as the 
	  
primary environmental driver of CD, we might expect CD to have lowered 
evolutionary fitness in individuals in the past afflicted with the condition. 
 
Diet, HLA, and the Pathophysiology of CD. Celiac disease is activated by 
proline-rich and glutamine-rich gluten proteins found in wheat and related 
proteins in rye and barley (Kagnoff 2007), and in rare cases oats (Koning 2012). 
Gluten is composed of two major protein types, gliadins and glutenins.  The high 
proline content of these peptides prohibits their complete digestion by gastric, 
pancreatic, and brush border enzymes in the gastrointestinal tract (Shan et al. 
2002).  Once ingested, gluten is partially digested into large high-proline and 
high-glutamine peptides, such as the 33 amino acid α-gliadin peptide, which can 
accumulate in the small intestine. 
 Although wheat gluten and related proteins are clearly the primary 
environmental trigger of CD, diet alone is not a sufficient explanation for the 
occurrence of the disease (Green and Cellier 2007; Kagnoff 2007). The genetic 
factors that influence pathogenesis of CD became evident and have been 
confirmed by various family and twin studies of CD (Risch 1987; Petronzelli et 
al. 1997; Bevan et al. 1999; Greco 2002; Nistico 2006).  This work has securely 
established HLA genes as the largest genetic components of CD risk. HLA 
molecules are antigen-presenting molecules, which bind antigenic peptides and 
present them to samples of circulating T-cells (Lawlor et al. 1990).  More 
	  
precisely, with respect to the cell, HLA class I molecules bind endogenous 
antigenic peptides and class II molecules bind exogenous antigenic peptides 
(Townsend and Bodmer 1989; Lawlor et al. 1990). Although early findings 
supported association to HLA class I alleles (Falchuk et al. 1972) and the class II 
HLA-DR locus (DeMarchi et al. 1979), further research has demonstrated that CD 
is most strongly associated with specific HLA class II alleles comprising HLA-
DQ.  Specifically, the alleles encoding the HLA-DQ2 and HLA-DQ8 molecules 
are necessary, but not singularly responsible for CD risk.  The majority of CD 
cases (90–95%) are associated with the HLA-DQ2 heterodimer, which is encoded 
by the alleles HLA-DQA1*05 and HLA-DQB1*02 either in cis, on the same 
haplotype, or in trans (Sollid 1989; Sollid and Thorsby 1990; Spurkland et al. 
1990). Additionally, a gene dosage effect has been observed for individuals 
homozygous for HLA-DQB1*02 (Karinen et al. 2006; Murray et al. 2007).  Of 
the approximately ten percent of cases not carrying the HLA-DQ2 heterodimer, 
half carry the HLA-DQ8 heterodimer (HLA-DQA1*03/HLA-DQB1*03:02) and 
the other half carry either HLA-DQA1*05 or HLA-DQB1*02 alone (Karell et al. 
2003). Further research has demonstrated the likely involvement of other genes in 
the extended HLA region in CD risk (Margaritte-Jeannin et al. 2004; Ahn et al. 
2012). 
 The role of the HLA-DQ2 and HLA-DQ8 heterodimers in CD 
pathogenesis is well understood.  HLA-DQ2 and HLA-DQ8 molecules contain 
	  
positively charged pockets, which preferentially bind to negatively charged 
peptides.  HLA-DQ heterodimers on antigen-presenting cells bind gluten peptides 
in which glutamine has been deamidated (converted to negatively charged 
glutamic acid) via tissue transglutaminase (Dieterich et al. 1997; Molberg et al. 
1998; van de Wal et al. 1998; Fleckenstein et al. 2002; Fleckenstein 2004).  The 
bound gluten-HLA-DQ complexes are then presented to populations of CD4+ T-
cells in the lamina propria of the small intestine. The T-cells that recognize the 
gluten-HLA-DQ complexes then produce pro-inflammatory cytokines such as 
interferon-𝛾, which likely play a role in the mucosal damage that is characteristic 
of CD (Nilsen et al. 1998).  Importantly, different wheat, rye, and barley each 
contain a variable repertoire of immunogenic peptides. Not all CD patients 
respond to the same sets of peptides (Koning 2012), which renders difficult the 
development of non-immunogenic grains (Kagnoff 2007; Koning 2012). 
 In addition to the adaptive immune response described above, gliadin 
peptides can also activate an innate immune response.  This innate immune 
response, which is characterized by an increase in the number of intra-epithelial 
lymphocytes (IELs) in CD patients is probably related to ongoing pathogenesis of 
CD such as the development of refractory CD (non-responsive villous atrophy 
and malabsorption) and the development of enteropathy-associated T-cell 
lymphoma (Kagnoff 2007).  Interleukin-15 (IL-15) is up-regulated in the lamina 
propria and the epithelium during the course of CD pathogenesis (Mention et al. 
	  
2003). The increased presence of IL-15 results in the activation of IEL’s 
expressing the natural killer immunoreceptor NK-G2D.  Activated IELs then 
become cytotoxic and kill enterocytes with MIC cell-surface expression (Hüe et 
al. 2004; Meresse et al. 2004; Green and Cellier 2007).  For a more thorough 
review of CD pathogenesis see (Green and Cellier 2007; Kagnoff 2007; Abadie et 
al. 2011). 
 
Non-HLA Genetic Factors: GWAS and Fine-Mapping Studies. Although 
HLA comprises only 40% of the genetic variance of CD risk, no compelling non-
HLA loci were shown to be associated with CD prior to the advent of genome-
wide association studies (GWAS) (Kumar et al. 2012). The first GWA study of 
CD in 2007 (Van Heel et al.) included a cohort of 778 CD individuals and 1,422 
controls from the UK.  This study tested for association to approximately 310,000 
single-nucleotide polymorphisms (SNPs) and identified a single risk locus in an 
LD block harboring IL2-IL21. Two follow up studies on the same sample (Hunt 
et al. 2008; Trynka et al. 2009) identified an additional nine non-HLA loci. A 
later CD GWAS by Dubois and colleagues (2010) included over 4,500 CD cases 
and over 11,000 controls from four populations (Finland, Italy, the Netherlands, 
the UK).  This study included replication of the 131 top SNPs in seven European 
cohorts comprising approximately 5,000 CD cases and 5,500 controls and added 
another 13 risk loci to the list of CD associated genomic regions.  Importantly, 
	  
this study also demonstrated that nearly 50% of CD risk SNPs are in close 
proximity to expression quantitative trait loci (eQTLs), suggesting a likely role for 
changes in levels of gene expression in CD.  As mentioned above, additional 
GWA studies have identified risk loci shared between CD and other autoimmune 
conditions such as T1DM, RA, CrD, and ulcerative colitis (UC) (Zhernakova et 
al. 2007, 2011; Smyth et al. 2008; Barrett et al. 2009; Festen et al. 2009, 2011; 
Cotsapas et al. 2011; Gutierrez-Achury et al. 2011).  These studies have 
illuminated the tremendously pleiotropic nature of loci underlying autoimmune 
and other immune related conditions.  For a comprehensive review of risk allele 
sharing among autoimmune diseases, see Ricaño-Ponce and Wijmenga (2013). 
 A major step forward in the identification and resolution of risk loci 
underlying CD was a fine-mapping study conducted by Trynka and colleagues 
(2011). Rather than using the same genotype arrays as earlier CD studies, which 
contained 300,000 to 550,000 SNPs ascertained primarily in Europeans and 
dispersed throughout the genome, this study utilized the Immunochip (Cortes and 
Brown 2011), a custom Illumina array designed to increase SNP coverage density 
in regions with existing associations to 12 immune-mediated diseases (including 
CD) in Europeans (~200,000 SNPs total).  Trynka and colleagues (2011) 
identified a total of 40 genomic loci (including HLA) associated with CD.  
However, the additional resolution from the Immunochip array allowed the 
researchers to identify multiple independent signals in 13 loci, for which alleles of 
	  
different SNPs in the same genomic region contribute independently to risk across 
CD cases. This brought the total number of non-HLA CD associated loci to 39 
with 57 independently associated SNPs and 29 signals confined to single genes. 
 
Genetic Architecture and Heritability. A large proportion of risk for CD can be 
attributed to genetic factors.  The most recent large-scale twin-study of heritability 
has estimated the narrow-sense heritability (h2) of CD at between 57% and 87%, 
with variation in the h2 estimate due to the assumed population prevalence 
(1/1000 and 1/91, respectively).  (Nistico 2006).  This estimate was not age 
specific.  Rather, mean age at diagnosis of twins in this study ranged from 0.5 to 
57 years.  However, 50% of twins were diagnosed before age three.  Further, this 
study did not explicitly control for the presence of gluten in the diet.  The fine-
mapping study by Trynka and colleagues (2011) has brought the total percentage 
of that genetic variance currently explained to ~53.7%, with 40% due to the 
primary HLA risk variants.  Some combination of other effects likely explains the 
remainder of the genetic variance that is expected from population data. 
 Traditional GWAS approaches are statistically underpowered to identify 
causal rare-variants due to the fact that sample sizes needed to establish a 
significant association with rare variants (MAF < 1%) are much larger than 
needed for common variants (Gorlov et al. 2008). Further, traditional genotyping 
arrays primarily consist of common variants.  It has been proposed that rare-
	  
variants may explain larger proportions of risk than common variants in certain 
cases (Bodmer and Bonilla 2008; Asimit and Zeggini 2010), particularly those 
that are population specific (Kumar et al. 2012). Therefore, although much of CD 
risk can be explained by a common disease/common variant model, new methods 
for identifying rare-variant associations hold the promise to discover additional 
rare risk loci underlying this condition (Asimit and Zeggini 2010).  Still, 
widespread support for a major role of low-frequency variants remains 
unsupported. The dense genotyping Immunochip analysis by Trynka and 
colleagues (2011) identified lower frequency variants (< 5%) at four loci (CD28-
CTLA4-ICOS, PTPN2, RGS1, SOCS1-PRM1-PRM2), all of low effect size (OR 
< 1.7). An exome sequencing study of a family of six segregating for CD failed to 
identify any rare causal variants (Szperl et al. 2011).  Finally, in a recent high-
coverage exome sequencing study of 20 risk loci with overlapping associations to 
six autoimmune diseases in 25 individuals, Hunt and colleagues (2013) estimate 
that rare variants contribute to less than 3% of the heritability explained by 
common variants at the risk loci included in the study.  Though rare-variants in 
coding regions appear to contribute little to disease risk, exploration of non-
coding regions may prove more fruitful. The statistical factors making 
identification of rare causal variants with larger effect sizes also make it 
impossible for current GWAS approaches to identify common variants with very 
	  
small effect sizes.  Doing so would require extremely large cohort sizes (Kumar et 
al. 2012). 
 Further, traditional models used to estimate h2 from population occurrence 
data typically assume that the trait does not involve gene-gene interactions 
(epistasis).  Failure to include epistasis in models of h2 where it does exist inflates 
the estimate of h2 for the trait (Zuk et al. 2012).  Recent developments in 
identifying epistatic interactions (Rao et al. 2011; Ma et al. 2012; Rajapakse et al. 
2012) hold promise for explaining some of the “missing” h2 underlying CD risk. 
 
Environmental Risk Factors. The remainder of CD risk must lie in 
environmental risk factors and gene by environment interactions.  Although the 
pathophysiology of CD is well understood, mysteries remain.  For example, 
environmental factors such as enteric viruses (Kagnoff 1984; Stene et al. 2006; 
Kagnoff 2007) may in some cases affect the permeability of the mucosal lining of 
the small intestine, allowing gluten peptides to access the underlying mucosal 
layers.  Additionally, variation in immunogenic peptides in wheat, rye, and barley 
may explain some of the variation in CD symptoms (Koning 2012). A more 
complete understanding of the non-genetic factors that contribute to CD will 
improve our ability to study the evolutionary history of this condition. 
 While ingestion of gluten and related proteins are well established as the 
driver of CD, the fact that such a small percentage of those with increased genetic 
	  
risk actually develop the condition suggests that other environmental triggers are 
likely involved in the pathogenesis of CD. 
 Much focus has been placed on understanding the relationship(s) between 
the human gut microbiota and disease pathogenesis (Fujimura et al. 2010).  
Recently, study of the human gut microbiome has been applied to CD 
pathogenesis (Sellito et al. 2012; Cheng et al. 2013; Sjöberg et al. 2013).  Almost 
a decade ago, Forsberg and colleagues (2004) noted the presence of rod-shaped 
bacteria in CD patients, but not control, suggesting a potential role for bacterial 
infection in breaking gluten tolerance in children.  More recently, a prospective 
study by Sellitto and colleagues (2012) tested the hypothesis that the entire gut 
microbial ecosystem is involved in the switch from gluten tolerance to 
autoimmune response in genetically susceptible individuals.  The authors tracked 
the changes in gut microbiome composition from birth to 24 months in 34 infants 
with HLA-DQ2 and/or HLA-DQ8 risk genotypes and known to be first-degree 
relatives of biopsy proven CD patients.  The infants were randomly assigned to 
two groups; one fed a gluten-free diet from 6-12 months, the other a gluten-
included diet.  All infants resumed normal feeding at 12 months.  The sample 
included 13 infants from each group that completed all protocol, 8 infants from 
each group were chosen randomly for final analysis.  The researchers show a 
significant increase in anti-gliadin antibodies (AGA), specifically 
immunoglobulin G (IgG) in the early exposure group compared to the late 
	  
exposure group after normalizing by time of exposure.  Additionally, they show 
that the gut microbiota of at-risk infants were lacking in members of the phylum 
Bacteroidetes and had higher abundance of the phylum Fermicutes, a composition 
directly opposed to that of non at-risk infants.  An earlier study by Palmer and 
colleagues (2007) illustrated that in healthy infants, the microbial ecosystem 
reaches a profile similar to that of adults within the first year of life.  In contrast, 
Sellitto and colleagues (2012) find that the gut microbiota of infants at risk for CD 
maintain immature gut microbiota, characterized by low levels of Bacteroidetes 
and high levels of Firmicutes, throughout the first two years of life.  The authors 
show that delayed exposure to gluten had an overall positive effect on prolonging 
gluten tolerance and delaying onset of CD autoimmunity.  They hypothesize that 
the introduction of gluten in an immature gut microbiome could trigger the 
development of autoimmunity. 
 In contrast, a slightly later study by Cheng and colleagues (2013) found no 
significant differences in the overall composition and diversity of gut microbiota 
(including Bacteroidetes) between a sample of 10 children with newly diagnosed 
CD (aged 3–14) and 9 healthy controls (aged 4–16).  Thus, the differences 
observed by Sellitto and colleagues (2012) may not persist into later childhood.  
Cheng and colleagues (2013), however, did identify a sub-population profile of 
eight genus-like bacteria that differed significantly between the CD cases and 
healthy controls. 
	  
 Others have noted a relationship between gut bacteria and CD 
development (Forsberg et al. 2004; Ou et al. 2009; Sanz et al. 2011; Sjöberg et al. 
2013).  Most recently, Sjöberg and colleagues (2013) demonstrate a relationship 
between IL-17A, a proinflammatory cytokine involved in antibacterial defense, 
gut microbiome composition, and CD pathogenesis.  The authors suggest that 
both gluten and CD associated bacteria, such as the rod-shaped bacterium 
Lachnoanaerobaculum umeaense provoke IL-17A production in the intestinal 
mucosa of CD patients.  They argue that the magnitude of the IL-17A reaction to 
gluten is largely influenced by the makeup of the gut microbiota, particularly the 
amount of CD associated bacteria present.  In line with the results of Sellitto and 
colleagues (2012) mentioned above, these authors posit that conditions leading to 
disturbances in the composition of the gut microbiota early in life can lead to 
long-term dysbiosis with surpluses of CD associated bacteria.  These abnormal 
microbiota compositions may influence the amount of IL-17A responses to gluten 
and constitute a major risk factor for contraction of CD in genetically at risk 
children. 
 While investigation of the human gut microbiota has revealed a potential 
role for variation in gut associated bacteria in CD development, the connection 
between genes and environmental risk factors have provided no clear 
understanding of the breakdown of gluten tolerance leading to downstream tissue 
damage. 
	  
 Fortunately, the primary environmental risk factor underlying CD risk 
(gluten) is known, which makes CD a useful model for studying the evolutionary 
genetics of complex disease, particularly within a biocultural evolutionary 
framework.  The well-understood history of grain domestication (Kilian et al. 
2009; Willcox 2012) by humans gives us additional information that we can use 
to illuminate the evolutionary history of CD.  Several researchers have argued that 
CD likely rose to its current frequency due to positive selection on risk variants 
from some beneficial effect on the immune system within the context of 
increasing human population density (Barreiro and Quintana-Murci 2010; 
Zhernakova et al. 2010; Abadie et al. 2011).  However, a more complex model of 
CD may be necessary to explain the history of the full network of genes eliciting 
the CD response. 
 
Evolution of CD Risk 
The CD Paradox. Knowledge of the worldwide prevalence of CD is incomplete 
but growing (Gandolfi et al. 2000; Catassi et al. 2001; Mäki et al. 2003; Greco et 
al. 2012; Riddle et al. 2012; Rubio-Tapia et al. 2012). Human populations 
consume the cereals that can induce CD in widely varying amounts (Abadie et al. 
2011). CD is more common among populations with European and Near Eastern 
ancestry, even though these are precisely the populations with the longest history 
of wheat, rye, and barley agriculture (Tresset and Vigne 2011; Zeder 2011). 
	  
Although the analogy is not entirely apt, we can contrast the pattern of CD with 
the global pattern of lactose intolerance (lactase persistence), in which the 
populations with the longest history of dairying and milk consumption are those 
with the greatest adaptation to lactose digestion. 
 The population incidence of CD increases with age, but it is nonetheless 
notable in children and young adults before and during the reproductive lifespan. 
Mortality and morbidity associated with CD would have exerted fitness costs in 
past populations. The persistence of CD therefore requires some explanation. 
 Several hypotheses present possible explanations: 
1.  Founder effects in ancient populations might have increased the 
frequency of deleterious CD risk alleles in at-risk populations. 
2.  CD risk alleles may have been increased in frequency by positive 
selection due to pleiotropic effects on other, non-CD phenotypes.   
3. The genetic architecture of CD may be such that most loci 
contributing to CD risk have only minor effects on risk, meaning 
that selection against CD would have miniscule to nonexistent 
effects on any single risk locus (Stranger et al. 2011).  
4. Balancing or frequency-dependent selection may have maintained 
some risk-associated variants at high frequencies in past 
populations. In particular, it seems likely that either long-term 
	  
balancing selection, including overdominance, frequency-
dependent selection, or selection in a fluctuating (pathogen) 
environment has led to the current distribution of HLA risk 
variants in the ancestors of present at-risk populations 
(Albrechtsen et al. 2010). 
 
HLA and Balancing Selection. Balancing selection is a common evolutionary 
mechanism underlying risk for many diseases in present populations.  The classic 
single-gene disease models with balancing selection are haemoglobinopathies, 
structural abnormalities of globin proteins.  The most famous case is sickle-cell 
disease (Frenette and Atweh 2007), in which the sickle-cell gene has been 
selected due to the advantage of heterozygous individuals in resisting malaria. 
Recognition of this evolutionary history was facilitated by the geographic 
association of hemoglobinopathies with historic malaria incidence, and the clear 
fitness costs to homozygotes in both the presence and absence of malaria. 
 Much evidence supports the role of recent natural selection in shaping the 
HLA region (Albrechtsen et al. 2010). Some HLA haplotypes have been 
directionally selected in recent human populations, but there is no clear pattern of 
directional selection on CD-risk-associated HLA haplotypes (Abadie et al. 2011). 
HLA has long been observed to be under balancing selection in human 
populations and ancestral hominins.  In fact, many HLA Class II alleles pre-date 
	  
the divergence of all hominids (Humans & Apes) (Bergström and Gyllensten 
1995).  In fact, Bergström and Gyllensten (1995) found that DQB1 and DQA1 in 
hominids possess some of the oldest polymorphism of all class II genes according 
to the ratio of nonsynonymous to synonymous polymorphism at non-antigen 
recognition site (ARS) codons.  While the DQ loci appear to possess some of the 
oldest allelic variation of all class II genes, they also maintain a relatively small 
number of alleles indicating long-term balancing selection in hominids. 
 This pattern holds within the human species as well.  In the largest 
sequence study of the HLA complex in humans to date, Buhler and Sanchez-
Mazas (2011) analyzed 2,062 DNA sequences representing seven HLA genes (A, 
B, Cw, DRB1, DQA1, DQB1, DPB1) in a sample of 23,500 individuals from 200 
worldwide populations.  The researchers found that DQA1 and DQB1 have the 
highest percentage of significant Tajima’s D values across human populations.  
DQA1 in particular has significantly positive values of Tajima’s D across nearly 
every European sample in the study, suggesting the maintenance of allelic 
variation due to some type of balancing or diversifying selection.  Relative to 
most other HLA loci, DQB1 alleles are less diverse in pairwise comparisons of 
populations within regions.  Buhler and Sanchez-Mazas (2011) suggest that this 
lack of allelic diversity may reflect purifying selection on DQB1 due to structural 
constraints on the formation of HLA-DQ heterodimers, but this hypothesis has yet 
to be formally tested. 
	  
 An earlier study by Solberg and colleagues (2008) found a similar result 
after examining the Ewens-Watterson test of homozygosity in a large composite 
global dataset of HLA allele frequencies to demonstrate that balancing selection is 
widespread among HLA loci.  The class II genes HLA-DQA1 and HLA-DQB1 
are among the most strongly selected loci in this study, showing signals of 
balancing selection in Europe, North Africa, and Southwest Asia, precisely where 
CD is most common. The primary causal CD heterodimer (DQ2) is present at 
substantial frequencies (>1%) in many populations worldwide but reaches 
frequencies as high as 25% in populations of North Africa and Europe where CD 
is most common (Traherne 2008; Gonzalez-Galarza et al. 2011).  The relatively 
high frequency of this heterodimer in Europeans may be, in part, due to recent 
expansion of the COX long-range HLA haplotype approximately 25,000 years 
ago (Smith et al. 2006; Traherne 2008). 
 Some researchers have argued that the cause of balancing selection in 
HLA is overdominance (Takahata and Nei 1990; Takahata et al. 1992) within 
environments with particular pathogen communities. Recent evidence pertaining 
to this hypothesis is mixed. Balancing selection based on fitness overdominance 
does not tend to increase identity-by-descent (IBD) in the region linked to a 
selected locus, yet Albrechtsen and colleagues (2010) found strong IBD signals 
for HLA. Strong IBD is itself a sign of selection, but is more likely produced by 
fluctuating selection due to coevolution of immunity with pathogens, for example 
	  
in a frequency-dependent pattern. HLA risk alleles account for approximately 
40% of the additive variance underlying CD risk, suggesting that balancing 
selection may in part explain the occurrence of CD in European and North 
African populations today.  
 Under this hypothesis, CD is a fitness-reducing side effect of selection 
associated with pathogens. Bioarchaeological evidence demonstrates that dietary 
and demographic transitions of the Holocene were detrimental to human health 
(Larsen 2006). Dietary specialization led to nutritional deficits and denser living 
conditions created ideal conditions for the spread of new pathogens, as 
documented by higher rates of porotic hyperostosis, cribra orbitalia, dental caries, 
linear enamel hypoplasias, tuberculosis, and trepanematoses in populations after 
the onset of agricultural production (Armelagos and Harper 2005; Larsen 2006).  
Genetic and archaeological evidence show the importance of adaptive evolution 
concurrent with large-scale demographic change over the last 10,000 years 
(Hawks et al. 2007). These observations provoke the hypothesis that the Holocene 
transition to agriculture was a time of strong natural selection on genes important 
to immunity. Providing that the genetic locus of largest effect in CD is HLA 
(Trynka et al. 2011), and that genetic loci associated with autoimmune diseases in 
general are enriched for long-range haplotype signals of recent positive selection 
(Barreiro and Quintana-Murci 2010), a plausible hypothesis to explain the present 
distribution of CD is that the recent shift in demography and settlement patterns in 
	  
human populations led to increased selection on immune-related genes due to 
elevated pathogen pressure. 
 
GWAS, Genetic Architecture, and Selection on Complex Traits. HLA is only 
one component of the overall additive genetic variance in CD risk. A large 
network of other loci is known to explain some of the additive variance. We refer 
to these loci as “background risk” loci, because (a) each contributes to CD risk 
only conditioned upon the presence of the major HLA risk alleles, and (b) each 
makes only a small contribution to CD risk. The evolution of this set of loci may 
have been shaped mainly by other phenotypic associations or by random genetic 
drift, meaning that they may show very heterogeneous patterns of variation with 
respect to each other. In order to discuss the evolution of background risk of CD, 
we must more deeply probe the dynamics of this broader set of loci. 
 GWAS have provided nearly all the links between non-HLA loci and CD 
risk. GWAS is an unbiased statistical approach to identify phenotype/allelic 
correlations, with respect to genomic structure and the etiology of the phenotype 
under consideration (Stranger et al. 2011). A major goal of GWAS is to provide 
information about the underlying biology of a trait.  Systems genetics approaches, 
which analyze GWAS and other association data in combination with functional 
genomics data, can be combined with database information approaches, such as 
gene ontology (GO) (Botstein et al. 2000), gene-set enrichment analysis (GSEA) 
	  
(Subramanian et al. 2005) and similar types of analysis (Stranger et al. 2011), to 
provide avenues for identifying the complete network that underlies a complex 
trait. 
 At this point it is important to clarify the term “network.” CD risk loci that 
have been identified by GWAS represent a network strictly in their joint 
association with the CD phenotype. Pathway analysis can additionally examine 
whether some or all of these genes interact via co-expression or co-involvement in 
other phenotypes. In the case of CD, pathway analysis of GWAS loci has 
facilitated the identification of several biochemical pathways underlying CD 
including T-cells, NK-cells, B-cells, and neutrophils (Kumar et al. 2012), greatly 
contributing to our understanding of CD pathogenesis. In that sense, different CD 
background risk loci are parts of different functionally integrated networks of 
genes, each related to a discrete biochemical pathway. Dietary gluten can, within 
a certain biochemical context, have major effects on these different pathways, and 
the pathogenesis of CD is modified by certain genes within those pathways. Yet 
these pathways have many phenotypic consequences beyond CD, and many of the 
genes in these pathways are not associated with CD risk. In that respect, the 
functional integration of CD risk loci is unclear. 
 In contrast to functional integration, evolutionary integration provides an 
alternative way of describing genetic systems. When different genes respond 
together to a single environmental pressure, independent or semi-distinct 
	  
functional pathways may come to exhibit patterns of similarity, either in genetic 
variation or differentiation. Evolutionary integration may be recognized by a 
common pattern of evidence for positive selection, balancing selection, loss of 
functional constraint, or differentiation among populations. Different populations 
that share common environmental factors may also help to illuminate networks of 
genes that respond to selection associated with similar environments (Hancock et 
al. 2010a, 2010b, 2011). 
 To the extent that a trait involves related functional networks of genes, 
both the environment and genetic architecture are necessary to drive evolutionary 
integration. CD and other immune-related conditions tend to have at least one 
locus contributing a majority of the genetic variance (HLA) in addition to many 
other loci with small effect (Stranger et al. 2011; Kumar et al. 2012). This genetic 
architecture of CD is similar to an exponential model of effect size, in which the 
non-HLA loci make increasingly tiny contributions to the additive variance in 
risk. HLA haplotypes account for approximately 40% of the additive genetic 
variance of CD and the currently known non-HLA variants together account for at 
most 14% (Trynka et al. 2011) (Figure 1). In this model, we expect that HLA 
should bear the majority of the negative fitness effects of CD. Indeed, any 
response to selection associated with CD will affect HLA genetic variation 40% / 
14% = 2.86 times more than all of the other background loci combined. 
Alternatively, if we consider that the largest contribution to cumulative 
	  
heritability of any single background locus is approximately 1%, then the 
response to selection on HLA is approximately 40% / 1% = 40 times greater than 
the response on the most heritable background locus.   
 We can conclude from these considerations that CD itself is unlikely to 
have driven evolutionary integration of a network of associated loci. However, it 
is implicit from the hypothesis that CD risk may be a side-effect of selection on 
some other phenotype that evolutionary integration may have arisen on CD risk 
loci from non-CD causes. The test of evolutionary integration is the pattern of 
evolutionary history of CD risk-associated genes. If these genes exhibit a common 
pattern of evolution, we may be able to discover which environmental or 
historical factors generated the present pattern of CD risk. Alternatively, if the 
evolutionary history of these loci has been heterogeneous, we may conclude that 
CD is an accident of unrelated evolutionary causes. 
 
Evolution of Non-HLA Risk Loci. We can evaluate the evolutionary history of 
CD risk-associated loci by several methods. Some researchers (Pickrell et al. 
2009; Barreiro and Quintana-Murci 2010; Zhernakova et al. 2010; Abadie et al. 
2011) have used the iHS method to infer a role for strong recent selection on 
some non-HLA GWAS risk loci in Europeans. For example, Zhernakova and 
colleagues (2010) found evidence of recent selection in or around the genes 
IL12A, IL18RAP, and SH2B3.  The risk variant in the SH2B3 gene is functionally 
	  
involved in the NOD2 recognition pathway, suggesting that it may have been 
positively selected to protect against bacterial infection.  The authors inferred a 
very recent onset of selection (between 1,200 and 1,700 years ago) by extended 
haplotype homozygosity (EHH) (Sabeti et al. 2002).  However, Sams and Hawks 
(2013) found that this haplotype is present in the genome of Ötzi, the Tyrolean 
Iceman, which dates to 5,300 years ago (Keller et al. 2012). The apparent 
antiquity of the allele does not necessarily conflict with evidence for recent strong 
selection, if a pre-existing rare allele was selected within the last 2,000 years, but 
the apparent contradiction may also be explained by the wide variance in 
estimates of time of onset of selection. A broader comparison of genes involved in 
the CD risk network showed a low heterozygosity for these loci in the Ötzi 
genome, suggesting that many of the risk loci most tightly associated with CD 
risk today are not present in this ancient individual. Along these lines, Fumagalli 
and colleagues (2011) show, after correcting for demography, that many non-
HLA genes associated with autoimmune disease are significantly correlated with 
pathogenic diversity.  These genes include nine previously associated with CD 
risk, further supporting a role for local adaptation to pathogens in shaping CD 
risk. 
 While the past 10,000 years was a time of significant selection pressures 
on the immune system, the present risk pattern of CD may also reflect earlier 
events. Non-HLA regions of the genome associated with CD risk are more likely 
	  
to show significant differences between continents than are loci chosen randomly 
from the genome (Sams and Hawks 2013). Genes contributing to CD risk stand 
out against the overall genome-wide pattern of population structure, specifically 
when comparing genetic samples from Europe against East Asia. Within 
continents, African populations show relatively high differentiation of the CD risk 
network compared to the genome-wide pattern. Two samples from China also 
diverged more highly than the genome-wide expectation. These results point to 
the possibility of selection affecting some of the genes that contribute to CD risk 
today, at the time of differentiation of European and Asian populations, and again 
within Africa. Although as noted above some loci show evidence based on iHS 
for recent selection in Europe, this does not drive differentiation of CD risk genes 
as a group relative to the rest of the genome (Sams and Hawks 2013). This 
observation weakens the hypothesis that the broad network of CD risk loci has 
experienced directional selection within the last 10,000 years, although 
demographic factors might explain the lack of differentiation across European 
populations.  For example, if a significant portion of the ancestry of present 
Europeans is found among early Neolithic Near Eastern agriculturalists as has 
been predicted from archaeological and genomic data (Sokal et al. 1991; Haak et 
al. 2010; Fu et al. 2012; Gamba et al. 2012; Pinhasi and Cramon-Taubadel 2012; 
Sánchez-Quinto et al. 2012; Skoglund et al. 2012), CD risk loci may have been 
	  
selected early enough in the history of this demographic event to have spread to 
all present European populations 
 These population comparisons point not to evolutionary integration of the 
CD risk network, but instead to a heterogeneity of environmental influences in 
past populations. The CD background risk network was affected by selection at 
different times and in different populations, with no uniformity or consistency. 
Further analysis of this pattern with explicit reference to effect sizes of CD-
associated loci confirms the lack of systematic integration, as the signal of 
selection at a CD-associated locus does not predict the effect-size of the locus on 
present risk (Figure 2). Hence, although the joint association network underlying 
CD risk in European populations today has not experienced the same selection 
dynamics as the rest of the genome, these genes have responded to different 
environments, not a single Neolithic pulse of adaptation. With respect to the 
background of risk outside of the HLA system, CD is not an evolutionary 
tradeoff. 
 
Conclusions about CD Evolution. Celiac disease is a trait on the border 
between simple and complex. Many risk loci are known, but one (HLA) accounts 
for much more of the additive variance than others (Trynka et al. 2011).  Given 
the strong evidence of ongoing balancing selection at the HLA-DQA1 and HLA-
	  
DQB1 haplotypes (cited above), HLA may explain the majority of the 
evolutionary paradox of CD. 
 But this mechanism leaves much unexplained. The Saharawi of North 
Africa, for example, have a 5.6% occurrence of CD, in comparison to 1–2% in 
Southern Europe, despite similar frequencies of the primary risk HLA-DQ 
haplotype (Catassi et al. 1999, 2001). What explains this difference in risk?  In 
contrast to many other populations of Europe and the Near East, wheat became a 
staple food among the Saharawi only within the last century, and is now 
introduced to the diet much earlier (in infancy) (Catassi et al. 2001). An intriguing 
possibility is that selection on HLA-DQ may be have led to a balance between CD 
risk and pathogen resistance after the spread of wheat, rye and barley agriculture 
during the Neolithic.  More refined analysis of HLA haplotypes in CD patients 
from multiple combinations and tests for gene-gene interactions may reveal such 
a pattern. 
 Non-HLA risk loci for CD show a much more complex pattern of 
interactions between ancient environments and present-day risk. Some of these 
loci do appear to have responded to selection on a recent timescale, but most 
show no evidence of selection individually. While some parts of the CD risk joint-
association network are connected by protein–protein interactions (Figure 1), the 
CD risk network as a whole consists of different functional biochemical pathways 
(Kumar et al. 2012). Each may have been influenced by different environmental 
	  
and historical factors, and overall there is no evidence for evolutionary integration 
among them. The pathogenesis of CD shows that the condition results from the 
functional and regulatory activity of these loci. These were influenced by different 
environmental pressures, at different times in human evolutionary history. Celiac 
disease is a side effect of evolution, apparently in multiple ancient environments. 
Its persistence despite the consumption of wheat in ancient human populations 
may be attributed both to balancing selection on HLA class II alleles and the low 
additive variance contributed by many other loci associated with CD risk. Other 
autoimmune conditions share a similar pattern of risk dominated by HLA class II 
variation and overlapping greatly with CD risk in many cases (Rioux et al. 2009; 
Cotsapas et al. 2011; Gutierrez-Achury et al. 2011; Ahn et al. 2012; Cifuentes et 
al. 2012). Celiac disease may provide a model for understanding the relations of 
the present risk of autoimmune conditions to past human environments. 
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Figure 1. Protein–protein interactions and effect-sizes among non-HLA celiac 
disease risk loci. Protein–protein interactions among non-HLA CD risk loci 
via the STRING (v.9.1) database (Franceschini et al. 2013), which is a 
database of known and predicted protein interactions derived from multiple 
contexts. Node colors reflect the number of independent associations to CD at 
the locus centered on each gene (Yellow = 1; Blue = 2; Green = 3). Relative 
node sizes reflect the total effect size of each locus, with independent signals 
at each locus summed. Edge thicknesses reflect the confidence in each 
interaction according to the STRING database. 
 
 
	   
 
Figure 2. Africa/Europe CD risk odds-ratio / FST test p-value rank order 
correlation. Rank order correlation between Africa/Europe genome-wide FST test 
p-values and CD risk locus odds-ratios reported by Trynka and colleagues (2011) 
demonstrating the lack of correlation between these two variables.  This pattern 
suggests that CD loci with larger effect-sizes have not been systematically subject 
to greater differentiation.  The correlation coefficient is r2 = 0.268. 
 
